BME:ALMPharmaceuticals
Assessing Almirall (BME:ALM) Valuation After Strong Earnings And Growth Guidance
Almirall’s latest earnings and guidance trigger fresh focus on the stock
Almirall (BME:ALM) has come into focus after reporting full year 2025 results alongside new 2026 guidance, combining higher sales, revenue and net income with an outlook for 9% to 12% net sales growth.
See our latest analysis for Almirall.
Despite the new 2026 guidance and the strong 2025 earnings update, Almirall’s recent momentum has cooled, with the share price at €12.02 and a 7 day share price return of a 6.39%...